Expanding the spectrum of IDH1 mutations in gliomas

Neonatal lethal Costello syndrome and unusual dinucleotide deletion/insertion mutations in HRAS predicting p.Gly12Val

(2012) Emma M.M. Burkitt-Wright et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-Base Extension

(2012) Marco Perizzolo et al.   BRAIN PATHOLOGY

Prognostic Value of IDH1 Mutations Identified with PCR-RFLP Assay in Glioblastoma Patients

(2012) Mateusz Bujko et al.   Molecular Diagnosis & Therapy

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

(2011) Akitake Mukasa et al.   CANCER SCIENCE

IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature

(2011) Prerana Jha et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications

(2011) R. Gupta et al.   JOURNAL OF CLINICAL PATHOLOGY

Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia

(2011) Keyur P. Patel et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients

(2011) Yiqun Zhang et al.   LEUKEMIA RESEARCH

Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

(2011) P S Ward et al.   ONCOGENE

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

(2010) Jörg Felsberg et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

(2010) Philippe Metellus et al.   ACTA NEUROPATHOLOGICA

IDH1 and IDH2: Not Your Typical Oncogenes

(2010) Zachary J. Reitman et al.   CANCER CELL

Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies

(2010) Craig Horbinski et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples

(2010) Prashanth Setty et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Scientific correspondence

(2010) S. Pusch et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

(2009) Yukinari Kato et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE